Obesity, Fatty Liver and Liver Cancer

Softcover Nachdruck of the original 1. Auflage 2018
ISBN: 978-981-13-4213-4
Verlag: Springer Nature Singapore

Buch, Englisch, Band 1061, 157 Seiten, Previously published in hardcover, Format (B × H): 178 mm x 254 mm, Gewicht: 381 g

Reihe: Advances in Experimental Medicine and Biology

This volume covers a state-of-the-art illustration of recent discoveries concerning obesity-related fatty liver diseases and liver cancer. The contents are extensive and comprehensive. It brings important topics in the field all together under one umbrella, from epidemiology and etiology, molecular pathogenesis, cellular biology, epigenetics, immunology, microbiology, animal models to therapeutic approaches and treatments. All the book contributors are leading experts in the field. It will appeal to researchers, clinicians and graduate students in obesity, fatty liver diseases, GI/Liver cancer field. It may also yield benefits for pharmaceutical companies with regard to drug discovery.

Zielgruppe

Research

Autoren/Hrsg.

Yu, Jun

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Hepatologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Adipositas, Adipositastherapie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Molekulare Medizin, Zellbiologie

Inhaltsverzeichnis

Chapter 1. Introduction.- Chapter 2. Epidemiology and etiology of NAFLD and associated HCC.- Chapter 3. Pathogenesis of NASH: How metabolic complications of overnutrition favour lipotoxicity and pro-inflammatory fatty liver disease.- Chapter 4. Chemokines and Chemokine Receptors in the Development of NAFLD.- Chapter 5. NAFLD related-HCC: the relationship with metabolic disorders.- Chapter 6. Hepatocellular carcinoma in obesity: Finding a needle in the haystack?.- Chapter 7. Dysregulated epigenetic modifications in the pathogenesis of NAFLD-HCC.- Chapter 8. The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease.- Chapter 9. Microbiota, obesity and NAFLD.- Chapter 10. Autophagy, NAFLD and NAFLD-related HCC.- Chapter 11. Animal models of non-alcoholic fatty liver diseases and its associated liver cancer.- Chapter 12. Current prevention and treatment options for NAFLD.

Über Autor(innen)

Prof. Jun Yu is Professor in Department of Medicine & Therapeutics, Director of Research Laboratory of Institute of Digestive Disease, Associate Director of State Key Laboratory of Digestive Disease and Faculty of Medicine in The Chinese University of Hong Kong.